Lipoproteins are complexes consisting of a lipid core of mainly triglycerides and cholesterol esters surrounded by a surface monolayer of phospholipids, free cholesterol and specific protein components named apolipoproteins . Most apolipoproteins undergo complex exchange reactions and serve many metabolic functions including transport, enzyme cofactors and receptor ligands. Except for the covalently linked apolipoprotein(a)-apolipoproteinB-100 (apo(a)-apoB) complex in Lipoprotein(a) [Lp(a)], apolipoproteins are non-covalently associated with each other and the lipid core.
Lipoprotein disorders are often associated with cardiovascular disease (CVD), atherosclerosis and other organ dysfunctions [2, 3]. To prevent and treat these diseases and to fully understand their cause, it is necessary to characterise the underlying metabolic disorders . The conventional initial approach to do this is by measuring concentrations of plasma lipids or apolipoproteins. However, abnormal concentrations of lipids and apolipoproteins can result from changes in the production, conversion or catabolism of lipoprotein particles. Therefore, although static measurements and functional assays are important techniques to gain first in vivo functional insights, it is necessary to study their metabolic pathway to understand the complexity of lipoprotein function and pathophysiology [4, 5].
Animal models cannot sufficiently replace human studies to explore lipoprotein metabolism due to substantial species specificity. This holds particularly true for conventional laboratory animals such as mice and rats which – unless genetically modified or induced by special diet - do not develop atherosclerosis (see review ). The same argument is valid for investigations using cellular model systems. Since the liver is the central organ responsible for lipoprotein metabolism and primary human hepatocytes are of only limited use in research, most cellular studies in lipoprotein metabolism have been conducted in human hepatoma cells lines. These lines express, secrete and assemble a lipoprotein pattern which is substantially different from the respective human counterpart .
For all these reasons, the in vivo investigation of metabolic pathways in human subjects is the ultimate approach to elucidate physiological or pathological functions of metabolites in the human body. Historically, such human kinetic studies were performed using radioactive tracers; this methodology is, however, nowadays of only restricted use. Therefore, stable-isotope tracer kinetic studies in human subjects with clear advantages regarding safety and technical issues have replaced the radiotracer methods to become an important research tool for achieving a quantitative understanding of the dynamics of metabolic processes in vivo.
The aim of this review is to shortly describe the methodology and illustrate how the approach has expanded our understanding of physiological mechanisms as well as the pathogenesis of disorders of human lipoprotein metabolism. We will then specifically address the assembly mechanism of the atherogenic Lp(a) complex and focus on the kinetics of apoB-containing lipoproteins in patients with chronic kidney disease. This patient group is well-known for its high risk for atherosclerotic complications and a 10- to 20-fold increased cardiovascular mortality compared to the general population .
2. Principles of tracer technology
Exogenous and endogenous labelling techniques have been used to study the in vivo metabolism of an endogenous molecule, the tracee (see review ). In the exogenous method, the same molecule, in form of a usually radioactively labelled tracer, is introduced into the bloodstream . In lipoprotein studies, this methodology first requires purification of the target molecule or particle and ex-vivo radiolabelling followed by reinfusion into the circulation. The physological integrity of the target molecule might, however, suffer from such procedure. Furthermore, in case of multiprotein complexes (which most lipoproteins are), the kinetics of individual protein components cannot be investigated by this approach. As an example, the investigation of in vivo kinetics of both protein components of Lp(a), as described in this article, to study its assembly mechanism would not be possible with the exogenous labelling approach.
In contrast, in endogenous labelling, a labelled precursor of the molecule of interest, in case of proteins usually a labelled amino acid, is used to label the target molecule by infusion into the circulation of a suitable proband. Ideally, the tracer can easily be detected and quantified, has the same kinetic behaviour as the tracee, and does not perturb the system. Usually, kinetic studies are performed in steady state, where the rates of input and output for a given unlabelled tracee substance are equal and time invariant. Thus, the information provided by the tracer reflects the behaviour of the tracee [10, 11]. At various times, the target protein or particle has to be purified from the blood of human probands and the amount of tracer is quantified to provide a kinetic curve. A mathematical model is then constructed to extract all the information contained in the kinetic curve. By fitting a model to the data, it is possible to calculate the parameters of the model that characterize the flux of molecules between kinetically homogeneous pools. For example, it is thus possible to investigate the whole pathway including production, conversion or catabolism of lipoprotein particles, information that cannot be obtained by static measurements alone.
The term stable isotope refers to a non-radioactive isotope of a given atom that is less abundant in a molecule within a biological system than the lightest naturally occurring isotope. The most common stable isotope used as metabolic tracer for apolipoprotein kinetic studies is [2H3]-leucine. Stable isotope tracers are much safer than radioactive tracers for both the study subject and the investigator. Furthermore, the duration of stable isotope experiments is normally less than 24 hours which is much shorter compared to radiotracer techniques which may need up to 14 days of examination .
2.1. Tracer administration
A tracer can be administered intravenously as either a single bolus injection, a primed constant infusion (i.e., a constant infusion given immediately after a priming bolus), or as a combination of both. The tracer bolus administration offers superior dynamics compared with the primed constant infusion, because the enrichment curves (the tracer ⁄ tracee ratios) after a bolus injection correspond to the impulse response of the system. It is therefore suitable to study components of lipoprotein metabolism with a slow rate of turnover. Another advantage of bolus administration is that it facilitates the determination of newly synthesized particles, as the intracellular precursor enrichment is greater at the start of the study. This argument therefore counts particularly when investigating kinetics of particle assembly, as described in 3.1.1. Practically, the bolus infusion is also most convenient for both subjects and investigators.
2.2. Multicompartment models for data analysis
Multicompartment modelling is a superior method to dissect the complexities of lipoprotein metabolism, and has been widely applied to systems in which material is transferred over time between compartments connected in a specific structure to permit the movement of material amongst the compartments .
Each compartment is assumed to be a homogenous entity within which the entities being modelled are equivalent. For instance, the compartments may represent different types of lipoprotein particles that are kinetically homogeneous and distinct from other material in the system. Very often, the data can be described by more than one model. To ensure that the best model is selected, it is necessary to carefully examine the fitting of the kinetic curve, to determine the precision of the parameter estimates, and to perform statistical tests to compare results obtained with different models. However, the complexity of a multicompartment model is usually a compromise for what is practically possible. A very simple model may not adequately describe the kinetic heterogeneity present within the system. A model that is too complex, on the other hand, will not be supported by experimental data and, hence, will have little predictive value. Furthermore, even if the development of models is based on experimental data, several assumptions are required in order to derive the model that is to be used. Thus, mathematical models do not determine the kinetics of lipids directly; rather, they derive an indirect approximation.
The software SAAM (Epsilon Group, Charlottesville, VA, USA) has become the first choice for modelling lipoprotein kinetic studies. The SAAM II program was recently developed by SAAM Inst., Inc., Seattle, WA, USA, and is frequently used to analyse lipoprotein tracer data using compartmental models [13, 14]. The primary kinetic parameter resulting after modelling with SAAM II is the fractional synthesis rate (FSR) which, under steady state conditions, is identical to the fractional catabolic rate (FCR) and has the dimension of pools/day. The reciprocal value of FSR/FCR is called retention time (RT, given in days) and indicates the residence time of the investigated tracee (the target apolipoprotein in our cases) in the circulation. The product of FSR multiplied by the concentration of tracee is called production rate (PR) and is usually expressed as mg/kg body weight/day.
3. Metabolism of apoB-containing lipoproteins
Dietary lipids are absorbed in the intestine and packaged into large, triglyceride-rich chylomicrons which undergo lipolysis to form chylomicron remnants. In the last step of the so-called exogenous lipoprotein pathway, these particles are finally taken up by the liver. The liver then secretes triglyceride-rich lipoproteins known as very low-density lipoproteins (VLDLs) representing the first step oft the endogenous lipoprotein pathway (Figure 1). Lipoprotein kinetic studies have shown that VLDLs are metabolically heterogeneous. Following lipolysis by endothelium-bound lipoprotein lipase (LPL) and hepatic lipase (HL), these particles are converted via intermediate-density lipoproteins (IDL, also called VLDL remnants) to low-density lipoprotein (LDL) or taken up by the liver. LDL is catabolized mainly by the liver or peripheral tissues via the LDL receptor. Increased plasma concentrations of LDL are a major risk factor for CVD. ApoB-100 is the major apolipoprotein of chylomicrons, VLDL, IDL and LDL.
Lipoprotein(a) [Lp(a)] consists of an LDL-like particle which is covalently bound to the glycoprotein apolipoprotein(a) [apo(a)] by disulfide linkage and derives from the liver  (Figure 2). Among individuals, Lp(a) plasma concentrations vary more than 1000-fold, ranging from less than 0.1 mg/dl to more than 300 mg/dl. Depending on the investigated population and the used genetic approach, it has been shown that between 30% and 90% of this variation in plasma concentrations of Lp(a) is determined by the apo(a) gene locus, encoding proteins from <300 to >800 kDa [16-18]. Apo(a) size is negatively correlated with Lp(a) concentrations, such that low-molecular-weight (LMW) apo(a) isoforms express on average high Lp(a) plasma concentrations, while high-molecular-weight (HMW) isoforms are usually associated with lower concentrations (reviewed in reference ). Elevated plasma concentrations of Lp(a) have been found associated with an increased risk of developing CVD in many studies which was confirmed by recent large meta-analyses [19, 20]. In vivo kinetic studies using radio-labeled Lp(a) indicated that the large differences in Lp(a) concentrations seen among individuals are determined by synthesis and not degradation [9, 21].
3.1. Biosynthesis of Lp(a)
Lp(a) has been the target of extensive and successful research particularly with respect to the unusually high degree of genetic control of its expression. In contrast, metabolism and physiological roles as well as pathogenicities of Lp(a) are still poorly understood, as recently reviewed by Dubé et al. . The mechanisms that control Lp(a) secretion and assembly were investigated mostly by means of cellular hepatocyte model systems, yielded contrasting results and thus remain highly controversially discussed (see review ). Assembly of apo(a) and apoB to Lp(a) is generally viewed as a two-step procedure [24, 25]. In a first step, distinct domains within the apoB molecule initially associate with apo(a) in a non-covalent interaction to bring the two molecules into close proximity. In a second step, a disulfide bond is formed between apo(a) cysteine 4057 and apoB cysteine 4326 residues [24, 26]. Whether this disulfide bond is formed through a spontaneous oxidation reaction or through a specific enzymatic reaction is unclear [27, 28].
The location of this assembly process is the subject of controversial discussion as well. Intracellular, extracellular and/or plasma membrane-associated assembly procedures have been reported to occur in various cell systems . Lp(a), like many other oligomeric protein complexes, may assemble in the endoplasmic reticulum of the hepatocyte and be secreted as a whole particle [29, 30]. Alternatively, newly synthesized apo(a) could bind extracellularly to preexisting LDL or VLDL circulating in the plasma. Most authors postulate an extracellular assembly of Lp(a) based on studies conducted in various cellular model systems. White
3.1.1. In vivo metabolism of Lp(a) and LDL in healthy subjects
We investigated by stable-isotope technology the metabolism of apo(a) and apoB-100, the two major Lp(a) protein components, in comparison to apoB of LDL in nine healthy probands. The metabolic data accumulating in this study after appropriate modeling present a scenario of virtually complete intracellular assembly of Lp(a) .
Mean FSR, RT and PR values of apo(a) from Lp(a) were similar to those of apoB from Lp(a) but significantly different from the kinetic parameters of LDL-apoB. The differences were particularly large between the PR values of LDL and Lp(a) since this parameter takes into account plasma concentrations that are much higher for LDL than for Lp(a).
Tracer/tracee data from Lp(a)-apo(a), Lp(a)-apoB, LDL-apoB and VLDL-apoB were analyzed based on the multicompartment model shown in Figure 3 in order to investigate whether Lp(a) assembles from circulating LDL or from
The kinetic parameters obtained from this
3.2. Lipoprotein metabolism in HD patients suffering from chronic kidney disease (CKD)
Dyslipidemia in patients with CKD and hemodialysis (HD) patients is distinct from other organ-specific diseases with far-reaching therapeutic consequences (see review ). It involves all lipoprotein classes, shows considerable variations depending on the stage of CKD [50, 51] and is further modified by concurrent diseases such as diabetes  and nephrotic syndrome . In addition, major qualitative compositional changes in lipoprotein particles, such as oxidation, glycation, carbamylation and formation of small dense LDL (sdLDL – see below) which render the particles more atherogenic, have been observed . Reduced activities of plasma cholesterol esterification and cholesterol ester transfer between lipoproteins – key factors for the so-called „reversed cholesterol transport“ – result in substantially abnormal lipid composition of virtually all lipoprotein classes in HD patients .
Plasma triglycerides start to increase in early stages of CKD and show the highest concentrations in nephrotic syndrome and in patients treated with peritoneal dialysis (PD). In pre-dialysis CKD patients, the accumulation of triglycerides is the consequence of both an increased PR and a decreased FCR of triglyceride-rich lipoproteins . The increased production of triglyceride-rich lipoproteins is possibly a consequence of impaired carbohydrate tolerance and enhanced hepatic VLDL synthesis . The reduced catabolism is likely due to decreased activities of LPL and HL [58, 59], two endothelium-associated lipases that cleave triglycerides into free fatty acids for energy production or storage.
Diminished catabolism results in the accumulation of IDL particles contributing to compositional and size heterogeneity of triglyceride-rich lipoproteins in plasma of CKD patients. IDL are rich in apoE, a ligand that is important for removal from the circulation by binding to the LDL receptor . The arterial wall therefore is exposed to high plasma concentrations of IDL which may predispose to atherosclerosis .
Elevated plasma concentrations of LDL cholesterol and –apoB are common in nephrotic syndrome and PD but do not occur in patients with advanced CKD, treated with HD. There are, however, qualitative changes in LDL in patients with CKD and dialysis patients. The fraction of sdLDL, which is considered to be highly atherogenic, is increased in HD patients. sdLDL is a subtype of LDL which penetrates the vessel wall more efficiently than normal LDL, becomes oxidized, and triggers atherosclerotic processes. In addition, sdLDL exert a high affinity for macrophages promoting their entry into the vascular wall to participate in the formation of foam cells and atherosclerotic plaques .
In kidney disease, elevated plasma Lp(a) concentrations are not only genetically determined but also a consequence of kidney failure . In predialysis CKD patients, Lp(a) concentrations are influencedby the glomerular filtration rate (GFR). In patients with HMW apo(a) isoforms but not in thosewith LMW apo(a) isoforms, plasma Lp(a) concentrations begin toincrease in stage 1 CKD before GFR starts to decrease .This isoform-specific increase in plasma Lp(a) concentrations wasobserved in several but not all studies in CKD and HD patients [50, 62-66]. In contrast,in patients with nephrotic syndrome [67, 68] and in PDpatients , increases in plasma Lp(a) concentrations occur in allapo(a) isoform groups, probably as a consequence of thepronounced protein loss and a subsequently increased productionin the liver . After successful kidney transplantation,a decrease in plasma Lp(a) can be observedin HD patients with HMW apo(a) isoforms [70, 71] and in PDpatients with all apo(a) isoform groups . Thus, the elevationof Lp(a) in CKD is due to non-genetic causes, mostlyinfluenced by the degree of proteinuria [50, 67] and less bythe cause of kidney disease .
In summary, the hallmarks of uremic dyslipidemia include hypertriglyceridemia and increased circulating concentrations of IDL, sdLDL and Lp(a). HD patients are characterised by normal LDL concentrations, whereas patients with nephrotic syndrome and CKD patients treated by PD are diagnosed with elevated LDL concentrations.
3.2.1. Dyslipidemia and CVD in CKD
Forty years ago, Lindner and colleagues described in their seminal report the excessive risk of CVD in HD patients for the first time . Later, Foley et al. extended these observations by reporting a 10 to 20 times higher mortality rate in HD patients compared to the general population . While in the general population high plasma concentrations of apoB-containing lipoproteins, low concentrations of HDL cholesterol and high total triglyceride concentrations are associated with an increased atherosclerotic cardiovascular risk , most investigations, including cross-sectional [75-78] and longitudinal [66, 79-87] studies, do not support the association between dyslipidemia and CVD in hemodialysed CKD populations or even observe opposite associations. Indeed, a worse survival among HD patients has been observed with low rather than high BMI , blood pressure  and serum/plasma concentrations of cholesterol . This seemingly paradoxical phenomenon is often called „reverse epidemiology“  and exemplified in crossing curves when relating BMI with mortality in HD patients and the general population .
While the BMI-associated death risk shows an almost linear negative gradient in HD patients , the relationship between plasma total cholesterol and mortality has been found to be U-shaped . The group with total cholesterol between 200 and 250 mg/dl had the lowest risk for death, whereas those with levels >350 mg/dl had a relative risk of 1.3-fold and those with levels <100 mg/dl had a relative risk of 4.2-fold. The association between low total cholesterol and increased mortality, however, was reduced after statistical adjustment for plasma albumin levels. This dichotomous relationship was confirmed in the Choices for Healthy Outcomes in Caring for ESRD (CHOICE) study , which showed a nonsignificant negative association of cardiovascular mortality with plasma total as well as non–HDL cholesterol levels in the presence of inflammation and/or malnutrition; in contrast, there was a positive association between total and non–HDL cholesterol and mortality in the absence of inflammation or malnutrition. These observations are compatible with the hypothesis that the inverse association of total cholesterol levels with mortality in dialysis patients is mediated by the cholesterol-lowering effect of malnutrition and/or systemic inflammation and not due to a protective effect of high cholesterol concentrations.
The association of Lp(a) with atherosclerotic complications and CVD has been investigated in numerous studies in dialysis patients. Like other atherogenic lipoproteins, Lp(a) has been found to contribute to the high cardiovascular burden [66, 79, 84, 95-97]. When apo(a) phenotyping was performed along with plasma Lp(a) concentrations, an association between the apo(a) K-IV repeat polymorphism and CV complications was consistently observed.
Two final considerations regarding the impact of classical risk factors for the development of CVD in CKD patients are, however, worth mentioning: the cardiovascular risk for an individual CKD patient at a given time point is the sum (or combination) of risk exposure before and after developing CKD. When taking Lp(a) concentrations and apo(a) isoforms as an example, a previously healthy subject with low Lp(a) concentrations and a HMW apo(a) isoform develops CKD with subsequently rising Lp(a) concentrations covering a relatively short period of his lifespan. A subject with LMW apo(a) isoform, on the other hand, has genetically caused elevated Lp(a) concentrations for his whole life which do not substantially increase after developing CKD. Since the HMW apo(a) carrier is exposed to elevated atherogenic Lp(a) for a much shorter period of his life, this condition has to be considered less CVD-prone than having LMW apo(a). This example demonstrates the importance of the „longitudinal“ factor when considering risk factors for CVD in CKD patients.
Finally, as already discussed in the introduction, the quantification of a target parameter deemed to be associated with or predictive for a disease can only provide a static picture and hardly reflects the true in vivo metabolism. Seemingly normal blood concentrations of suspected marker candidates can only be validated by kinetic studies in humans and have been therefore performed also in CKD patients. They have provided novel and unexpected information regarding the physiology and pathology of atherogenic apoB-containing lipoproteins (see review ).
3.2.2. Delayed in vivo catabolism of LDL and IDL in HD patients as potential cause of premature atherosclerosis
For better understanding the atherogeneity of apoB-containing lipoproteins in HD patients and to resolve the apparent discrepancy between their obviously impaired lipoprotein metabolism and e.g. normal LDL plasma concentrations, we studied the in vivo kinetics of VLDL, IDL and LDL by stable isotope technology in HD patients and compared them to those of healthy controls .
This study demonstrated for the first time severely decreased FCRs of IDL- and LDL-apoB in HD patients as compared to controls (Figure 4), whereas the in vivo kinetics of VLDL did not change significantly. A decreased FCR of IDL- and LDL-apoB is identical to a prolonged RT of these highly atherogenic particles. The longer RT of these lipoproteins results in an extended exposure to oxidation for IDL and LDL in a highly oxidative environment. This is in line with experimental data showing a highly significant correlation of 5-hydroxy-2-aminovaleric acid (HAVA) in LDL, an oxidation product of apoB, with LDL RT in normolipidemic controls . In accordance with these results, two previously conducted randomized placebo-controlled studies revealed a significant reduction in composite cardiovascular disease endpoints when HD patients were treated for two years with supplementation of antioxidants such as vitamin E  or acetylcysteine .
Most remarkably, the observed impaired metabolism of apoB-containing lipoproteins is accompanied by normal concentrations of LDL-apoB and elevated levels of IDL-apoB (Figure 4), in line with previous reports which found increased concentrations of IDL as an independent risk factor for atherosclerosis in HD patients . A closer look at the kinetic data reveals that the normal concentrations of LDL are the result of a combination of decreased FCR and PR. This pattern therefore demonstrates convincingly the strength of kinetic studies in contrast to simply quantifying blood concentrations of a target marker such as LDL concentrations. Its normal concentrations are masked by two metabolic disorders which neutralise each other and result in normal values such as observed in the general population. The altered lipoprotein metabolism therefore puts HD patients at high risk for developing atherosclerotic disease despite their normal total and LDL cholesterol concentrations. Since most lipid-lowering drugs act by “normalising” the RT of the major atherogenic lipoproteins IDL and LDL , these drugs are expected to correct some of the basic defects of the severely disturbed lipoprotein metabolism in HD patients. Therefore, kinetic studies on the impact of lipid-lowering medication on the lipoprotein metabolism in CKD patients were a logic consequence of the observed, above-described findings (see chapter 3.2.5.).
Due to the laborious nature of these studies and the complexity of the metabolic modeling, only few studies have been performed so far in CKD patients either by radiotracer or stable isotope technology. Our kinetic data seem to contrast with a previously published turnover study in Finnish HD patients performed with conventional radiotracer techniques. While the authors found decreased LDL clearance rates in predialysis CKD patients  they could not find a significant difference in LDL-apoB FCR between HD patients and controls . More recently, Prinsen et al., by using stable isotopes, found unchanged FCRs for LDL-apoB in CKD patients treated with peritoneal dialysis . Chan et al. injected radio-labeled VLDL into HD patients with or without hyperlipidemia and found decreased FCRs of VLDL-apoB and IDL-apoB (the latter only in hyperlipidemic patients) . LDL kinetics were not investigated in this study. The reason for these discrepancies is not clear. There might be ethnic differences in the lipoprotein metabolism between the investigated patient populations of different ethnic origin. One major difference between our and the Finnish study is an age difference between patients and controls in our but not in the Finnish study. Our control subjects were considerably younger than the HD patients (35 vs. 51 years). At first glance, this age difference might explain to some extent the dramatic differences found in our study, since LDL clearance rates have been repeatedly described to decrease with age presumably due to down-regulated hepatic LDL receptor expression in the elderly [108, 109]. Based on the results of these studies, an age difference of 15 years (as observed in our work) would result in an approximately 10% change in FCR values and could therefore not explain the more than two-fold difference in our study. The observed differences in kinetic parameters can therefore not be explained by age differences between study groups.
Several mechanisms may contribute to our observations. First, the diminished LDL catabolism in HD patients might be explained by a possible contribution of LDL uptake by the healthy human kidney which does not function appropriately (or at all) in chronic kidney failure. In fact, glomerular cells like mesangial or epithelial cells have been shown
3.2.3. Kinetics of Lp(a) in hemodialysis patients
We previously performed
Comparing kinetic data in HD patients  with those in patients with nephrotic syndrome  points to fundamental differences in the metabolism of Lp(a) and other proteins between these two patient groups. Patients with nephrotic syndrome do not differ with respect to the FCR of Lp(a) compared to controls but have increased Lp(a) PRs . It is well known that nephrotic patients show a generally increased lipoprotein synthesis of lipoproteins . Since kidney function is relatively well preserved in nephrotic syndrome, a decreased clearance of Lp(a) in these patients is not likely to be expected. Metabolic differences between nephrotic and dialysis patients are not only evident for Lp(a) but also for albumin. Whereas the FCR of albumin in HD patients is similar or even reduced compared to controls, the FCR in patients with nephrotic syndrome is increased [116, 117].
3.2.4. Consequences of the impaired metabolism of atherogenic lipoproteins in HD patients
The observation of markedly decreased FCRs of apoB of LDL and IDL as well as apo(a) and apoB in Lp(a) causes a prolonged RT of these highly atherogenic lipoproteins. Due to the long retention period, “aged” lipoprotein complexes are thus more susceptible for alterations such as oxidation damage, which was shown to be associated with accelerated atherogenesis in HD patients . Previous kinetic studies investigated the metabolism of the two LDL subclasses, “buoyant” LDL1 and the smaller cholesterol-poor “dense” LDL2, in subjects with familial defective apoB-100 (FDB). The authors found a more than four-fold longer RT for small dense LDL2 in those patients as compared to normolipidemic controls . It was therefore suggested that oxidative damage of an “aged” LDL2, which is present in large concentrations in both blood and the subendothelial space, may be an important mechanism for the development of premature atherosclerosis in patients with familial defective apoB-100. Since the LDL-like particle of Lp(a) is compositionally similar to LDL2 , it is tempting to speculate that the increased RT of circulating Lp(a) might pose an additional risk factor for the increased incidence of cardiovascular disease in HD patients.
3.2.5. Influence of statin treatment on kinetic parameters in hemodialysed patients
In the general population, therapy with HMG-CoA-reductase inhibitors (statins) which inhibit endogenous cholesterol biosynthesis has shown to improve outcome in several atherosclerotic diseases [119, 120]. The inhibition of cholesterol biosynthesis subsequently leads to up-regulation of LDL receptors and therefore increased clearance and thus reduced RT of circulating LDL . Statins also have a beneficial role as anti-inflammatory agents, which is independent of their lipid-lowering effect. Inflammation is highly prevalent in patients with CKD and is consistently associated with cardiovascular morbidity and mortality. In line with this metabolic background, the first studies in HD patients demonstrated a substantial normalisation of the dyslipidemic plasma profile and reduced progression of renal disease [121, 122] and in one study also reduced mortality  in these patients.
In contrast and quite surprisingly, three previously conducted large, randomized, placebo-controlled trials on statin treatment in CKD patients had not led to significant benefits regarding their primary cardiovascular outcome. Two of those studies, the German Diabetes Dialysis (4D) Study and the Study to Evaluate the Use of Rusovastatin in Subjects on Regular Hemodialysis (AURORA) were performed on HD patients, one study, the Assessment of Lescol in Renal Transplantation (ALERT) Study on patients who had undergone kidney transplantation. Their primary endpoints (death of cardiovascular cause, nonfatal myocardial infarction or nonfatal stroke) were virtually unchanged [124-126]. However, there has been a promising risk reduction in the secondary endpoint ‘all cardiac events combined’ in one study . A simulated study of exactly the same trial using a large historical database with more than 10.000 patients also demonstrated that statin use was associated with some benefit . A comprehensive review of outcome data from the 4D and AURORA trials found no benefit of statin therapy in either the whole study group of HD patients or after stratification for inflammatory marker levels . More recently, another, much larger trial including 9270 patients with chronic kidney disease, the Study of Heart and Renal Protection (SHARP) could show a significant risk reduction in cardiovascular events in a mixed population of patients with kidney disease including 2/3 predialysis and 1/3 HD patients treated with a combination of a statin and ezitimibe. This effect did not differ between HD and predialysis patients .
Based on our previous studies on lipoprotein kinetics in HD patients and the above-described conflicting results regarding their cardiovascular risk profile after statin treatment, we examined by stable-isotope technology the in vivo kinetics of apoB-containing particles in HD patients before and after treatment with atorvastatin (Schwaiger et al., unpublished).
In this study we described for the first time effects of HMG-CoA reductase inhibition on apoB metabolism in CKD patients treated with HD. Low-dose atorvastatin, given for three months to six male patients, lowered, as expected, concentrations of VLDL- and LDL-apoB, both accompanied by a significant increase of their FCR, while hepatic production of both apolipoproteins was not altered. This led, as expected, to a lower RT of these atherogenic apoB-containing particles comparable to RT values of healthy subjects with normal kidney function. The observed findings therefore argue for a beneficial effect of statin therapy regarding cardiovascular events in HD patients similar to described for the general population.
To understand why statins have surprisingly failed to reduce cardiovascular events in HD patients, the basic mechanisms underlying the pathophysiology of CVD in CKD must be critically considered. In contrast to the general population, CKD patients suffer, in addition to dyslipidemia, from several further complex comorbid conditions including diabetes mellitus, hypertension, oxidative stress, inflammation, insulin resistance, anemia and disturbances in mineral metabolism. Lipid lowering therapy by statins have the potential to ameliorate only some but no all of those conditions (see review ). Taken together, statin therapy in CKD maybe recommended based on our kinetic studies on apoB-containing lipoproteins, optimally combined with medication to treat atherogenic non-lipid factors in HD patients.
Kinetic in vivo studies in human subjects are superior to many methodological approaches including animal and cell culture models and thus represent the ultimate approach to understand basic metabolic pathways in humans. They have clearly revolutionized human lipoprotein research and have particularly resulted in novel insights into the metabolism of atherogenic apoB-containing lipoproteins some of which have been the subject of our previous investigations and object of this review.
We would like to thank Ramona Berberich, Linda Fineder, Michael E. Frischmann, Tatsuo Hosoya, Katsunori Ikewaki, Paul König, Florian Kronenberg, Seibu Mochizuki, Yoshinobu Nakada, Ulrich Neyer, Keio Okubo, Hermann Salmhofer Jürgen R. Schäfer, Johannes P. Schwaiger, Horst Schweer, Alex Starke, Evi Trenkwalder and Emanuel Zitt for invaluable contributions over many years within the various projects covered in this chapter. Funding support from the Austrian Science Fund (P10090-MED, P12358-MED), the Austrian National Bank (6721/4, 9331) and Pfizer-Austria (ATV-A-02-007G) is greatly appreciated.
Mahley RW, Innerarity TL, Rall SCJ, Weisgraber KH. New Insights into the Assembly and Metabolism of ApoB-Containing Lipoproteins from in vivo Kinetic Studies: Results on Healthy Subjects and Patients with Chronic Kidney DiseaseJ Lipid Res 1984 25 1277 1294
Kwan B. C. Kronenberg F. Beddhu S. Cheung A. K. New Insights into the Assembly and Metabolism of ApoB-Containing Lipoproteins from in vivo Kinetic Studies: Results on Healthy Subjects and Patients with Chronic Kidney DiseaseJ Am Soc Nephrol 2007 18 1246 1261
Williams K. J. Tabas I. New Insights into the Assembly and Metabolism of ApoB-Containing Lipoproteins from in vivo Kinetic Studies: Results on Healthy Subjects and Patients with Chronic Kidney DiseaseArterioscler Thromb Vasc Biol 1995 15 551 561
Boren J. Taskinen M. R. Adiels M. New Insights into the Assembly and Metabolism of ApoB-Containing Lipoproteins from in vivo Kinetic Studies: Results on Healthy Subjects and Patients with Chronic Kidney DiseaseJ Intern Med 2012 271 166 173
Adiels M. Olofsson S. O. Taskinen M. R. Boren J. New Insights into the Assembly and Metabolism of ApoB-Containing Lipoproteins from in vivo Kinetic Studies: Results on Healthy Subjects and Patients with Chronic Kidney DiseaseArterioscler Thromb Vasc Biol 2008 28 1225 1236
Jawien J. Nastalek P. Korbut R. New Insights into the Assembly and Metabolism of ApoB-Containing Lipoproteins from in vivo Kinetic Studies: Results on Healthy Subjects and Patients with Chronic Kidney DiseaseJ Physiol Pharmacol 2004 55 503 517
Javitt NB. Hep G2 cells as a resource for metabolic studies: Lipoprotein, cholesterol, and bile acids.FASEB J 1990 4 161 168
Foley RN, Parfrey PS, Sarnak MJ. New Insights into the Assembly and Metabolism of ApoB-Containing Lipoproteins from in vivo Kinetic Studies: Results on Healthy Subjects and Patients with Chronic Kidney DiseaseAm J Kidney Dis 1998S 112 119
Invest Krempler F. Kostner G. M. Bolzano K. Sandhofer F. Turnover of. lipoprotein(a in. man J. Clin 1980 65 1483 1490
Barrett PH, Chan DC, Watts GF. Thematic review series: patient-oriented research.Design and analysis of lipoprotein tracer kinetics studies in humans. J Lipid Res 2006 47 1607 1619
Ikewaki K. Rader D. J. Sakamoto T. et al. New Insights into the Assembly and Metabolism of ApoB-Containing Lipoproteins from in vivo Kinetic Studies: Results on Healthy Subjects and Patients with Chronic Kidney DiseaseJ Clin Invest 1993 92 1650 1658
Ikewaki K. Schaefer J. R. ME Frischmann et. al New Insights into the Assembly and Metabolism of ApoB-Containing Lipoproteins from in vivo Kinetic Studies: Results on Healthy Subjects and Patients with Chronic Kidney DiseaseArterioscler Thromb Vasc Biol 2005 25 2615 2622
Metabolism Barrett P. H. BM Bell Cobelli. C. et al. S. A. A. M. I. I. Simulation analysis. modeling software. for tracer. pharmacokinetic studies. 1998 47 484 492
Adv Exp Med Biol Cobelli C. Foster D. M. Compartmental models. theory practice using. the S. A. A. M. I. I. software system. 1998 445 79 101
- 15. Utermann G. Lipoprotein(a). In: Scriver C. R., Beaudet A. L., Sly W. S.,Valle D. (eds), The metabolic bases of inherited disease, New York, McGraw Hill Inc., 2001:2753-2787.
Genetic variants associated with Lp(a) lipoprotein level and coronary disease. N Engl J Med Clarke R. Peden J. F. Hopewell J. C. et al. 2009 361 2518 2528
Hum Genet Kraft H. G. Köchl S. Menzel H. J. Sandholzer C. Utermann G. The apolipoprotein(a. gene a. transcribed hypervariable. locus controlling. plasma lipoprotein(a. concentration 1992 90 220 230
Genetics of the Lp(a)/apo(a) system in an autochthonous Black African population from the Gabon. Eur J Hum Genet Schmidt K. Kraft H. G. Parson W. Utermann G. 2006 14 190 201
Bostom A. G. Gagnon D. R. Cupples L. A. et al. A. prospective investigation. of elevated. lipoprotein (a. detected by. electrophoresis cardiovascular disease. in women. The Framingham. Heart Study. 1994 90 1688 1695
JAMA Erqou S. Kaptoge S. Perry P. L. et al. Lipoprotein(a concentration. the risk. of coronary. heart disease. stroke nonvascular mortality. J. A. M. 2009 302 412 423
The inverse association of plasma lipoprotein(a) concentrations with apolipoprotein(a) isoform size is not due to differences in Lp(a) catabolism but to differences in production rate. J Clin Invest Rader D. J. Cain W. Ikewaki K. et al. 1994 93 2758 2763
Dube JB, Boffa MB, Hegele RA, Koschinsky ML. Lipoprotein(a): more interesting than ever after 50 years.Curr Opin Lipidol 2012 23 133 140
The seventh myth of lipoprotein(a): where and how is it assembled? Curr Opin Lipidol Dieplinger H. Utermann G. 1999 10 275 283
Proc Natl Acad SciU.S.A. Brunner C. Kraft H. G. Utermann G. Müller H. J. Cys40 of apolipoprotein(a. is essential. for lipoprotein(a. assembly 1993 90 11643 11647
J. A two-step model for lipoprotein(a) formation. J Biol Chem Trieu V. N. Mc Conathy W. J. A. two-step model. for lipoprotein(a. formation 1995 270 15471 15474
Mc Cormick S. P. Ng J. K. Taylor S. Flynn L. M. Hammer R. E. Young S. G. New Insights into the Assembly and Metabolism of ApoB-Containing Lipoproteins from in vivo Kinetic Studies: Results on Healthy Subjects and Patients with Chronic Kidney DiseaseProc Natl Acad Sci U.S.A. 1995 92 10147 10151
Identification of sequences in apolipoprotein(a) that maintain its closed conformation: a novel role for apo(a) isoform size in determining the efficiency of covalent Lp(a) formation. Biochemistry Becker L. Cook P. M. Koschinsky M. L. 2004 43 9978 9988
Catalysis of covalent Lp(a) assembly: evidence for an extracellular enzyme activity that enhances disulfide bond formation. Biochemistry Becker L. ME Nesheim Koschinsky. M. L. 2006 45 9919 9928
MJ Gething Sambrook. J. New Insights into the Assembly and Metabolism of ApoB-Containing Lipoproteins from in vivo Kinetic Studies: Results on Healthy Subjects and Patients with Chronic Kidney DiseaseNature 1992 355 33 45
Protein oligomerization in the endoplasmic reticulum. Annu Rev Cell Biol Hurtley S. M. Helenius A. 1989 5 277 307
White AL, Lanford RE.Biosynthesis and metabolism of lipoprotein(a). Curr Opin Lipidol 1995 6 75 80
White AL, Rainwater DL, Lanford RE.Intracellular maturation of apolipoprotein[a] and assembly of lipoprotein[a] in primary baboon hepatocytes. J Lipid Res 1993 34 509 517
Intracellular metabolism of human apolipoprotein(a) in stably transfected Hep G2 cells. Biochemistry Lobentanz E. M. Krasznai K. Gruber A. et al. 1998 37 5417 5425
Identification of the cysteine residue in apolipoprotein(a) that mediates extracellular coupling with apolipoprotein B-100. J Biol Chem Koschinsky M. L. Côté G. P. Gabel B. Van der Hoek Y. Y. 1993 268 19819 19825
Expression of a recombinant apolipoprotein(a) in HepG2 cells. Evidence for intracellular assembly of lipoprotein(a). J Biol Chem Bonen D. K. Hausman A. M. L. Hadjiagapiou C. Skarosi S. F. Davidson N. O. 1997 272 5659 5667
Identification and partial characterization of discrete Apolipoprotein B containing lipoprotein particles produced by human hepatoma cell line HepG2. Biochemistry Dashti N. Alaupovic P. Knight-Gibson C. Koren E. 1987 26 4837 4846
Biochim Biophys Acta Krempler F. Kostner G. M. Bolzano K. Sandhofer F. Lipoprotein(a is. not a. metabolic product. of other. lipoproteins containing. apolipoprotein B. 1979 575 63 70
Studies on the metabolism of the lipoprotein Lp(a) in man. Atherosclerosis Krempler F. Kostner G. Bolzano K. Sandhofer F. 1978 30 57 65
- 39. Morrisett J, Gaubatz J, Nava L, et al. Metabolism of apo(a) and apoB-100 in human lipoprotein(a). In: Catapano A., Gotto Jr. A. M., Smith L. C.,Paoletti R. (eds), Drugs affecting lipid metabolism, Dordrecht, The Netherlands, Kluwer Academic Publishers and Fondazione Giovanni Lorenzini, 1993:161-167.
Judge H, Walsh BW, Sacks FM. Metabolism of Apo(a) and ApoB100 of lipoprotein(a) in women: effect of postmenopausal estrogen replacement. J Clin Endocrinol Metab Su W. Campos H. Judge H. Walsh B. W. Sacks F. M. Metabolism of. Apo(a Apo B1. of lipoprotein(a. in women. effect of. postmenopausal estrogen. replacement 1998 83 3267 3276
The metabolism of lipoprotein(a) and other apolipoprotein B-containing lipoproteins: a kinetic study in humans. Atherosclerosis Demant T. Seeberg K. Bedynek A. Seidel D. 2001 157 325 339
Jenner JL, Seman LJ, Millar JS, et al.The metabolism of apolipoproteins (a) and B-100 within plasma lipoprotein (a) in human beings. Metabolism 2005 54 361 369
In vivo stable-isotope kinetic study suggests intracellular assembly of lipoprotein(a). Atherosclerosis ME Frischmann Ikewaki. K. Trenkwalder E. et al. 2012in press).
In vivo turnover study demonstrates diminished clearance of lipoprotein(a) in hemodialysis patients. Kidney Int ME Frischmann Kronenberg. F. Trenkwalder E. et al. 2007 71 1036 1043
Shames DM, Havel RJ.De novo production of low density lipoproteins: Fact or fancy. J Lipid Res 1991 32 1099 1112
Increased clearance of low density lipoprotein precursors in patients with heterozygous familial defective apolipoprotein B-100: a stable isotope approach. J Lipid Res Pietzsch J. Wiedemann B. Julius U. et al. 1996 37 2074 2087
J, Demant T, Stewart JP, et al. Apolipoprotein B metabolism and the distribution of VLDL and LDL subfractions. J Lipid Res Packard C. J. Demant T. Stewart J. P. et al. Apolipoprotein B. metabolism the distribution. of V. L. D. L. subfractions L. D. L. 2000 41 305 318
Synthesis and secretion of lipoproteins by human hepatocytes in culture. In Vitro Cell Dev Biol ME Bouma Pessah. M. Renaud G. Amit N. Catala D. Infante R. 1988 24 85 90
J Biol Chem Kagawa A. Azuma H. Akaike M. Kanagawa Y. Matsumoto T. Aspirin reduces. apolipoprotein(a (apo(a. production in. human hepatocytes. by suppression. of apo(a. gene transcription. 1999 274 34111 34115
J Am Soc Nephrol Kronenberg F. Kuen E. Ritz E. et al. Lipoprotein(a serum. concentrations apolipoprotein(a phenotypes. in mild. moderate renal. failure 2000 11 105 115
J Am Soc Nephrol Kronenberg F. Kuen E. Ritz E. et al. Apolipoprotein-I A. serum V. concentrations are. elevated in. patients with. mild moderate renal. failure 2002 13 461 469
Krentz AJ.Lipoprotein abnormalities and their consequences for patients with type 2 diabetes. Diabetes Obes Metab 2003Suppl 1:S 19 27
Dyslipidemia and nephrotic syndrome: recent advances. J Ren Nutr Kronenberg F. 2005 15 195 203
Atherogenic lipoproteins in end-stage renal disease. Am J Kidney Dis Shoji T. Ishimura E. Inaba M. Tabata T. Nishizawa Y. 2001S 30 33
Plasma cholesterol metabolism in end-stage renal disease. Difference between treatment by hemodialysis or peritoneal dialysis. J Clin Invest Dieplinger H. Schoenfeld P. Y. Fielding C. J. 1986 77 1071 1083
Batista MC, Welty FK, Diffenderfer MR, et al. Apolipoprotein A-I, B-100, and B-48 metabolism in subjects with chronic kidney disease, obesity, and the metabolic syndrome.Metabolism 2004 53 1255 1261
Lipid abnormalities in renal disease. Kidney Int Appel G. 1991 39 169 183
Pathogenic roles of post-heparin lipases in lipid abnormalities in hemodialysis patients. Kidney Int Chan M. K. Persaud J. Varghese Z. Moorhead J. F. 1984 25 812 818
Role of hepatic lipase in intermediate-density lipoprotein and small, dense low-density lipoprotein formation in hemodialysis patients. Kidney Int Suppl Oi K. Hirano T. Sakai S. Kawaguchi Y. Hosoya T. 1999S 227 228
Science MS Brown Goldstein. J. L. A. receptor-mediated pathway. for cholesterol. homeostasis 1986 232 34 47
Littlewood TD, Bennett MR.Apoptotic cell death in atherosclerosis. Curr Opin Lipidol 2003 14 469 475
Elevated plasma concentrations of lipoprotein(a) in patients with end-stage renal disease are not related to the size polymorphism of apolipoprotein(a). J Clin Invest Dieplinger H. Lackner C. Kronenberg F. et al. 1993 91 397 401
Multicenter study of lipoprotein(a) and apolipoprotein(a) phenotypes in patients with end-stage renal disease treated by hemodialysis or continous ambulatory peritoneal dialysis. J Am Soc Nephrol Kronenberg F. König P. Neyer U. et al. 1995 6 110 120
Am J Kidney Dis Milionis H. J. MS Elisaf Tselepis. A. Bairaktari E. Karabina S. A. Siamopoulos K. C. Apolipoprotein(a phenotypes. lipoprotein(a concentrations. in patients. with renal. failure 1999 33 1100 1106
Kidney Int Stenvinkel P. Heimburger O. Tuck C. H. Berglund L. Apo(a)-isoform size. nutritional status. inflammatory markers. in chronic. renal failure. 1998 53 1336 1342
Inflammation enhances cardiovascular risk and mortality in hemodialysis patients. Kidney Int Zimmermann J. Herrlinger S. Pruy A. Metzger T. Wanner C. 1999 55 648 658
Kidney Int Kronenberg F. Lingenhel A. Lhotta K. et al. The apolipoprotein(a. size polymorphism. is associated. with nephrotic. syndrome 2004 65 606 612
Ann Intern Med Wanner C. Rader D. Bartens W. et al. Elevated plasma. lipoprotein(a in. patients with. the nephrotic. syndrome 1993 119 263 269
de Sain-van der Velden MG, Reijngoud DJ, Kaysen GA, et al.Evidence for increased synthesis of lipoprotein(a) in the nephrotic syndrome. J Am Soc Nephrol 1998 9 1474 1481
Arterioscler Thromb Kronenberg F. König P. Lhotta K. et al. Apolipoprotein(a phenotype-associated. decrease in. lipoprotein(a plasma. concentrations after. renal transplantation. 1994 14 1399 1404
Eur J Hum Genet Kronenberg F. Lhotta K. Konig P. Margreiter R. Dieplinger H. Utermann G. Apolipoprotein(a isoform-specific. changes of. lipoprotein(a after. kidney transplantation. 2003 11 693 699
Atherosclerosis Kerschdorfer L. Konig P. Neyer U. et al. Lipoprotein(a plasma. concentrations after. renal transplantation. a. prospective evaluation. after . years of. follow-up 1999 144 381 391
Accelerated atherosclerosis in prolonged maintenance hemodialysis. N Engl J Med Lindner A. Charra B. Sherrard D. J. Scribner B. H. 1974 290 697 701
Prediction of coronary heart disease using risk factor categories. Circulation Wilson P. W. D’Agostino R. B. Levy D. Belanger A. M. Silbershatz H. Kannel W. B. 1998 97 1837 1847
Atherosclerotic cardiovascular disease risks in chronic hemodialysis patients. Kidney Int Cheung A. K. MJ Sarnak Yan. G. et al. 2000 58 353 362
Effect of apolipoprotein E polymorphism on serum lipid, lipoproteins, and atherosclerosis in hemodialysis patients. Am J Kidney Dis Guz G. Nurhan Ozdemir. F. Sezer S. et al. 2000 36 826 836
J Am Soc Nephrol Koch M. Kutkuhn B. Trenkwalder E. et al. Apolipoprotein B. fibrinogen H. D. L. cholesterol apolipoprotein(a phenotypes. predict coronary. artery disease. in hemodialysis. patients 1997 8 1889 1898
Stack AG, Bloembergen WE.Prevalence and clinical correlates of coronary artery disease among new dialysis patients in the United States: a cross-sectional study. J Am Soc Nephrol 2001 12 1516 1523
Circulation MD Cressman Heyka. R. J. Paganini E. P. O’Neil J. Skibinski C. I. Hoff H. F. Lipoprotein(a is. an independent. risk factor. for cardiovascular. disease in. hemodialysis patients. 1992 86 475 482
Mortality risk factors in patients treated by chronic hemodialysis. Report of the Diaphane collaborative study. Nephron Degoulet P. Legrain M. Reach I. et al. 1982 31 103 110
Different impact of biomarkers as mortality predictors among diabetic and nondiabetic patients undergoing hemodialysis. J Am Soc Nephrol Hocher B. Ziebig R. Altermann C. et al. 2003 14 2329 2337
Predictors of stroke in patients receiving chronic hemodialysis. Kidney Int Iseki K. Fukiyama K. 1996 50 1672 1675
Kidney Int Suppl Koda Y. Nishi S. Suzuki M. Hirasawa Y. Lipoprotein(a is. a. predictor for. cardiovascular mortality. of hemodialysis. patients 1999S 251S253.
The low molecular weight apo(a) phenotype is an independent predictor for coronary artery disease in hemodialysis patients: a prospective follow-up. J Am Soc Nephrol Kronenberg F. Neyer U. Lhotta K. et al. 1999 10 1027 1036
Kidney Int Suppl Ohashi H. Oda H. Ohno M. Watanabe S. Sakata S. as Lipoprotein(a a. risk factor. for coronary. artery disease. in hemodialysis. patients 1999S 242S244.
Carotid plaques and their predictive value for cardiovascular disease and all-cause mortality in hemodialysis patients considering renal transplantation: a decade follow-up. Am J Kidney Dis Schwaiger J. P. Lamina C. Neyer U. et al. 2006 47 888 897
J Am Soc Nephrol Shoji T. Emoto M. Shinohara K. et al. Diabetes mellitus. aortic stiffness. cardiovascular mortality. in end-stage. renal disease. 2001 12 2117 2124
Association of morbid obesity and weight change over time with cardiovascular survival in hemodialysis population. Am J Kidney Dis Kalantar-Zadeh K. JD Kopple Kilpatrick. R. D. et al. 2005 46 489 500
Reverse epidemiology of hypertension and cardiovascular death in the hemodialysis population: the 58th annual fall conference and scientific sessions. Hypertension Kalantar-Zadeh K. Kilpatrick R. D. Mc Allister C. J. Greenland S. JD Kopple 2005 45 811 817
Paradox of risk factors for cardiovascular mortality in uremia: is a higher cholesterol level better for atherosclerosis in uremia? Am J Kidney Dis Nishizawa Y. Shoji T. Ishimura E. Inaba M. Morii H. 2001S 4 7
What is so bad about reverse epidemiology anyway? Semin Dial Kalantar-Zadeh K. 2007 20 593 601
Reverse epidemiology of cardiovascular risk factors in maintenance dialysis patients. Kidney Int Kalantar-Zadeh K. Block G. Humphreys M. H. JD Kopple 2003 63 793 808
Lowrie EG, Lew NL.Death risk in hemodialysis patients: the predictive value of commonly measured variables and an evaluation of death rate differences between facilities. Am J Kidney Dis 1990 15 458 482
Traditional cardiovascular disease risk factors in dialysis patients compared with the general population: the CHOICE Study. J Am Soc Nephrol Longenecker J. C. Coresh J. Powe N. R. et al. 2002 13 1918 1927
Longenecker JC, Klag MJ, Marcovina SM, et al. Small apolipoprotein(a) size predicts mortality in end-stage renal disease: The CHOICE study.Circulation 2002 106 2812 2818
Arterioscler Thromb Kronenberg F. Kathrein H. König P. et al. Apolipoprotein(a phenotypes. predict the. risk for. carotid atherosclerosis. in patients. with end-stage. renal disease. 1994 14 1405 1411
LongeneckerJC, Klag MJ, Marcovina SM, et al. High lipoprotein(a) levels and small apolipoprotein(a) size prospectively predict cardiovascular events in dialysis patients. J Am Soc Nephrol 2005 16 1794 1802
Kinetic studies of atherogenic lipoproteins in hemodialysis patients: do they tell us more about their pathology? Semin Dial Kronenberg F. Ikewaki K. Schaefer J. R. Konig P. Dieplinger H. 2007 20 554 560
Oxidation of apolipoprotein B-100 in circulating LDL is related to LDL residence time. In vivo insights from stable-isotope studies. Arterioscler Thromb Vasc Biol Pietzsch J. Lattke P. Julius U. 2000E 63 67
Secondary prevention with antioxidants of cardiovascular disease in endstage renal disease (SPACE): randomised placebo-controlled trial. Lancet Boaz M. Smetana S. Weinstein T. et al. 2000 356 1213 1218
The antioxidant acetylcysteine reduces cardiovascular events in patients with end-stage renal failure: a randomized, controlled trial. Circulation Tepel M. van der Giet M. Statz M. Jankowski J. Zidek W. 2003 107 992 995
Intermediate-density lipoprotein as an independent risk factor for aortic atherosclerosis in hemodialysis patients. J Am Soc Nephrol Shoji T. Nishizawa Y. Kawagishi T. et al. 1998 9 1277 1284
Vega GL, Grundy SM.Influence of lovastatin therapy on metabolism of low density lipoproteins in mixed hyperlipidaemia. J Intern Med 1991 230 341 350
Decreased clearance of low-density lipoprotein in patients with chronic renal failure. Kidney Int Hörkkö S. Huttunen K. Korhonen T. Kesäniemi Y. A. 1994 45 561 570
Decreased clearance of low-density lipoprotein in uremic patients under dialysis treatment. Kidney Int Hörkkö S. Huttunen K. Kesäniemi Y. A. 1995 47 1732 1740
Kidney Int Prinsen B. H. Rabelink T. J. Romijn J. A. et al. A. broad-based metabolic. approach to. study V. L. D. L. apo B1. metabolism in. patients with. E. S. R. D. patients treated. with peritoneal. dialysis 2004 65 1064 1075
Clin Nephrol Chan P. C. Persaud J. Varghese Z. Kingstone D. Baillod R. A. Moorhead J. F. Apolipoprotein B. turnover in. dialysis patients. its relationship. to pathogenesis. of hyperlipidemia. 1989 31 88 95
Influence of age on the metabolism of plasma low density lipoproteins in healthy males. J Clin Invest Ericsson S. Eriksson M. Vitols S. Einarsson K. Berglund L. Angelin B. 1991 87 591 596
Impact of age on the metabolism of VLDL, IDL, and LDL apolipoprotein B-100 in men. J Lipid Res Millar J. S. Lichtenstein A. H. Cuchel M. et al. 1995 36 1155 1167
Receptor-mediated lipoprotein uptake by human glomerular cells: comparison with skin fibroblasts and HepG2 cells. Nephrol Dial Transplant Quaschning T. Koniger M. Kramer-Guth A. et al. 1997 12 2528 2536
Handling of low-density lipoprotein by the renal tubule: release of fragments due to incomplete degradation. J Lab Clin Med AA Pegoraro Gudehithlu. K. P. Cabrera E. et al. 2002 139 372 378
Renovascular arteriovenous differences in Lp[a] plasma concentrations suggest removal of Lp[a] from the renal circulation. J Lipid Res Kronenberg F. Trenkwalder E. Lingenhel A. et al. 1997 38 1755 1763
Urinary excretion of apo(a) fragments. Role in apo(a) catabolism. Arterioscler Thromb Vasc Biol Kostner K. M. Maurer G. Huber K. et al. 1996 16 905 911
Relationship to plasma levels of lipoprotein(a). J Clin Invest Mooser V. Seabra M. C. Abedin M. Landschulz K. T. Marcovina S. Hobbs H. H. Apolipoprotein(a kringle. 4-containing fragments. in human. urine 1996 97 858 864
Kaysen GA, de Sain-van der Velden MG.New insights into lipid metabolism in the nephrotic syndrome. Kidney Int Suppl 1999S 18 21
Increased albumin and fibrinogen synthesis in hemodialysis patients with normal nutritional status. J Am Soc Nephrol Giordano M. De Feo P. Lucidi P. et al. 2001 12 349 354
Kaysen GA.Albumin turnover in renal disease. Miner Electrolyte Metab 1998 24 55 63
Antibody to oxidized low-density lipoprotein and cardiovascular mortality in end-stage renal disease. Kidney Int Shoji T. Fukumoto M. Kimoto E. et al. 2002 62 2230 2237
Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S).Lancet 1994 344 1383 1389
Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med CP Cannon Braunwald. E. Mc Cabe C. H. et al. 2004 350 1495 1504
Fried LF, Orchard TJ, Kasiske BL.Effect of lipid reduction on the progression of renal disease: a meta-analysis. Kidney Int 2001 59 260 269
Effects of lipid-lowering drugs on intermediate-density lipoprotein in uremic patients. Kidney Int Suppl Nishizawa Y. Shoji T. Tabata T. Inoue T. Morii H. 1999S 134 136
Seliger SL, Weiss NS, Gillen DL, et al. HMG-CoA reductase inhibitors are associated with reduced mortality in ESRD patients.Kidney Int 2002 61 297 304
Fellstrom BC, Jardine AG, Schmieder RE, et al.Rosuvastatin and cardiovascular events in patients undergoing hemodialysis. N Engl J Med 2009 360 1395 1407
Rosuvastatin in diabetic hemodialysis patients. J Am Soc Nephrol Holdaas H. Holme I. Schmieder R. E. et al. 2011 22 1335 1341
Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis. N Engl J Med Wanner C. Krane V. Marz W. et al. 2005 353 238 248
Clin J Am Soc Nephrol Chan K. E. Thadhani R. Lazarus J. M. Hakim R. M. Modeling the. . D. Study statins. cardiovascular outcomes. in long-term. hemodialysis patients. with diabetes. 2010 5 856 866
Nat Rev Nephrol Krane V. Wanner C. Statins inflammation. kidney disease. 2011 7 385 397
The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial. Lancet Baigent C. MJ Landray Reith. C. et al. 2011 377 2181 2192
Statins in the management of dyslipidemia associated with chronic kidney disease. Nat Rev Nephrol Epstein M. Vaziri N. D. 2012 8 214 223